Insights

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jason Westin, MD, participated in a debate regarding choice of CAR T-cell therapy versus novel therapy for older adults with diffuse large B-cell lymphoma.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Gareth Morgan, MD, examines the role of tumor complexity and microenvironment in the development of multiple myeloma.

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.